Tucatinib Recommended Dosage and Daily Dosage

Tucatinib, also known as tucatinib, is a selective HER2 tyrosine kinase inhibitor, mainly used to treat HER2-positive metastatic breast cancer, especially for patients who have previously received trastuzumab, pertuzumab and T-DM1. Tucatinib, in combination with capecitabine and trastuzumab, has been recommended in multiple international guidelines and has been proven to have significant advantages in prolonging progression-free survival and overall survival.

According to common usage regimens abroad, the recommended dosage of tucatinib is 300 mg twice a day, usually administered orally. This frequency must also be strictly followed when used in combination with other drugs. The medication time should be as fixed as possible, with an interval of 12 hours in the morning and evening. It is recommended to take it before and after meals, but it is best to maintain a consistent medication habit. The tablet should be swallowed whole each time, and should not be broken, chewed or dissolved to ensure stable efficacy.

The treatment cycle of tucatinib needs to be determined according to the patient's condition and tolerance. Generally, on the premise that the disease does not progress and side effects are controllable, it will be continued until disease progression or intolerable adverse reactions occur. It is worth noting that when tucatinib is used in combination with capecitabine and trastuzumab, the dose adjustment needs to refer to the reaction performance of other drugs. If adverse reactions such as abnormal liver function and diarrhea occur, the drug may need to be temporarily discontinued or the dose reduced.

During the course of medication, patients are advised to regularly review liver function indicators and monitor common side effects such as weight and diarrhea. Before taking the medicine, you should truthfully inform your doctor of all the medicines you are taking, and avoid taking them with strong CYP3A inducers or inhibitors to avoid affecting the metabolism and blood concentration of tucatinib in the body. If patients experience obvious discomfort during medication, they should promptly communicate with their doctor to adjust the treatment plan.

Reference materials:https://www.drugs.com